1. Home
  2. POLE vs NMRA Comparison

POLE vs NMRA Comparison

Compare POLE & NMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • POLE
  • NMRA
  • Stock Information
  • Founded
  • POLE 2024
  • NMRA 2019
  • Country
  • POLE United States
  • NMRA United States
  • Employees
  • POLE N/A
  • NMRA N/A
  • Industry
  • POLE
  • NMRA
  • Sector
  • POLE
  • NMRA
  • Exchange
  • POLE NYSE
  • NMRA Nasdaq
  • Market Cap
  • POLE 299.8M
  • NMRA 121.0M
  • IPO Year
  • POLE 2024
  • NMRA 2023
  • Fundamental
  • Price
  • POLE $10.39
  • NMRA $1.34
  • Analyst Decision
  • POLE
  • NMRA Buy
  • Analyst Count
  • POLE 0
  • NMRA 8
  • Target Price
  • POLE N/A
  • NMRA $9.29
  • AVG Volume (30 Days)
  • POLE 11.2K
  • NMRA 1.6M
  • Earning Date
  • POLE 01-01-0001
  • NMRA 08-05-2025
  • Dividend Yield
  • POLE N/A
  • NMRA N/A
  • EPS Growth
  • POLE N/A
  • NMRA N/A
  • EPS
  • POLE N/A
  • NMRA N/A
  • Revenue
  • POLE N/A
  • NMRA N/A
  • Revenue This Year
  • POLE N/A
  • NMRA N/A
  • Revenue Next Year
  • POLE N/A
  • NMRA N/A
  • P/E Ratio
  • POLE $58.65
  • NMRA N/A
  • Revenue Growth
  • POLE N/A
  • NMRA N/A
  • 52 Week Low
  • POLE $9.94
  • NMRA $0.61
  • 52 Week High
  • POLE $11.16
  • NMRA $17.19
  • Technical
  • Relative Strength Index (RSI)
  • POLE N/A
  • NMRA 69.27
  • Support Level
  • POLE N/A
  • NMRA $0.72
  • Resistance Level
  • POLE N/A
  • NMRA $1.18
  • Average True Range (ATR)
  • POLE 0.00
  • NMRA 0.10
  • MACD
  • POLE 0.00
  • NMRA 0.03
  • Stochastic Oscillator
  • POLE 0.00
  • NMRA 74.14

About POLE ANDRETTI ACQUISITION CORP. II

Andretti Acquisition Corp II is a blank check company.

About NMRA Neumora Therapeutics Inc.

Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.

Share on Social Networks: